Exercise Programming for Women With Hypermobility: Evidence-Based Approaches for Clinical Practice

Abstract

Women with hypermobility face unique challenges in musculoskeletal health, exercise tolerance, and injury risk. This review synthesizes current evidence on exercise programming strategies for women with hypermobility, emphasizing the clinical implications, pathophysiological mechanisms, and guideline-based recommendations to optimize outcomes. The discussion integrates epidemiological trends, diagnostic approaches, risk stratification, and recent advances in therapeutic modalities, providing practitioners with a comprehensive framework for personalized care.

Introduction

Joint hypermobility, characterized by the ability of joints to move beyond normal physiological limits, is prevalent among women and often underrecognized in clinical settings. The heterogeneity of hypermobility syndromes, including hypermobile Ehlers-Danlos syndrome (hEDS) and generalized joint hypermobility (GJH), necessitates tailored exercise interventions. This article critically evaluates the evidence on exercise prescription for women with hypermobility, focusing on clinical efficacy and safety.

Epidemiology / Disease Burden

Hypermobility affects approximately 10-20% of women, with higher prevalence during adolescence and in certain ethnic groups. The gender predilection is attributed to hormonal, anatomical, and connective tissue differences. Women with hypermobility are at increased risk for chronic pain syndromes, soft tissue injuries, proprioceptive deficits, and functional impairment, contributing to substantial disease burden and diminished quality of life. Epidemiological data indicate comorbidities such as anxiety, orthostatic intolerance, and gastrointestinal dysmotility are more frequent in this population, compounding clinical complexity.

Pathophysiology

The underlying pathophysiology involves alterations in collagen and extracellular matrix proteins, resulting in increased ligamentous laxity and joint instability. Estrogen and other sex hormones further modulate connective tissue properties, explaining the higher prevalence in women. Mechanistically, impaired proprioception, neuromuscular control deficits, and autonomic dysfunction contribute to symptomatology. These factors influence exercise tolerance, injury risk, and adaptation to physical activity, underscoring the need for individualized programming.

Risk Factors

Key risk factors for symptomatic hypermobility include female sex, positive family history, early menarche, and participation in activities demanding flexibility (e.g., dance, gymnastics). Additional contributors include poor muscle strength, joint trauma history, and coexisting connective tissue disorders. Hormonal fluctuations, particularly during pregnancy or menstrual cycles, can exacerbate symptoms and should be considered in exercise planning.

Clinical Features

Women with hypermobility may present with musculoskeletal pain, recurrent sprains, joint subluxations or dislocations, fatigue, and soft tissue injuries. Non-musculoskeletal manifestations such as dysautonomia, gastrointestinal complaints, and anxiety are also common. On examination, the Beighton score and Brighton criteria aid in diagnosing generalized hypermobility, while skin hyperextensibility, scarring, and easy bruising suggest syndromic variants such as hEDS.

Diagnosis

Diagnosis is primarily clinical, integrating history, physical examination, and standardized scoring systems (e.g., Beighton score, Brighton criteria). Differential diagnosis includes Marfan syndrome, Loeys-Dietz syndrome, and other heritable disorders of connective tissue. Laboratory and imaging studies are reserved for excluding alternative etiologies or assessing complications. Multidisciplinary assessment, incorporating rheumatology, physiotherapy, and genetics, is often required for complex cases.

Treatment & Management

Exercise is a cornerstone of management, aiming to enhance joint stability, proprioception, and functional capacity. Evidence supports tailored neuromuscular training, strength-based protocols, and proprioceptive exercises over generic stretching or high-impact regimens. Emphasis is placed on closed-chain kinetic exercises, progressive resistance training, and low-impact aerobic activities. Physiotherapists should monitor for adverse responses such as increased pain, fatigue, or injury. Adjunctive measures include joint protection strategies, orthotics, and pain education. Multidisciplinary care with input from occupational therapists, psychologists, and pain specialists optimizes long-term outcomes.

Recent Advances / Emerging Therapies

Recent research highlights the potential benefits of sensorimotor retraining, virtual reality-based rehabilitation, and individualized pacing strategies for women with hypermobility. Advances in wearable technology facilitate objective monitoring of joint movement, fatigue, and adherence. Innovative protocols integrating cognitive-behavioral approaches and graded exposure are increasingly adopted for persistent pain and kinesiophobia. Pharmacologic interventions remain adjunctive, with limited efficacy for musculoskeletal symptoms.

Guideline Recommendations

Clinical guidelines advocate for early identification of hypermobility and individualized exercise programming, emphasizing strength, proprioception, and functional stability. The 2017 international EDS classification and recent consensus statements recommend avoidance of high-impact activities and excessive stretching. Ongoing patient education regarding symptom self-management, activity pacing, and injury prevention is essential. Multidisciplinary collaboration is strongly endorsed to address the multisystemic nature of hypermobility syndromes in women.

Conclusion

Optimizing exercise programming for women with hypermobility requires a nuanced understanding of the unique pathophysiological, clinical, and psychosocial factors involved. Evidence-based, individualized interventions focusing on neuromuscular control, strength, and proprioception are central to improving function and reducing morbidity. Continued research and guideline evolution will further refine best practices, ensuring women with hypermobility receive comprehensive, safe, and effective care.